September 10, 2025

Therapeutic strategies for graft-versus-host disease in the new era.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Overview of therapeutic strategies and biomarkers for acute and chronic gvhd, highlighting recent developments.

Graft-versus-host disease remains a major cause of mortality post-transplantation, with 40-60% of patients suffering from acute gvhd.
Recent advancements in biomarkers and risk stratification strategies have enabled better management of acute gvhd and chronic gvhd.
A new severity classification system for acute gvhd could improve preemptive treatment strategies for patients undergoing transplants.
Three new drugs have been approved for the treatment of chronic gvhd, marking significant progress in therapeutic options.

Masako Toyosaki (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 10, 2025

View Full Paper

Ask AI

Bookmark

Authors

Overview of therapeutic strategies and biomarkers for acute and chronic gvhd, highlighting recent developments.

Graft-versus-host disease remains a major cause of mortality post-transplantation, with 40-60% of patients suffering from acute gvhd.
Recent advancements in biomarkers and risk stratification strategies have enabled better management of acute gvhd and chronic gvhd.
A new severity classification system for acute gvhd could improve preemptive treatment strategies for patients undergoing transplants.
Three new drugs have been approved for the treatment of chronic gvhd, marking significant progress in therapeutic options.

Masako Toyosaki (2025) studied this question.

View Full Paper

Ask AI

Bookmark